Pfizer Inc. (NYSE:PFE) Position Lowered by Physicians Financial Services Inc.

Physicians Financial Services Inc. decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 13.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 44,018 shares of the biopharmaceutical company’s stock after selling 6,780 shares during the period. Physicians Financial Services Inc.’s holdings in Pfizer were worth $1,267,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Moneta Group Investment Advisors LLC lifted its holdings in Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after acquiring an additional 160,963,976 shares during the last quarter. Norges Bank bought a new position in Pfizer in the fourth quarter worth about $3,150,472,000. Charles Schwab Investment Management Inc. lifted its holdings in Pfizer by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after acquiring an additional 9,393,992 shares during the last quarter. Morgan Stanley lifted its holdings in Pfizer by 10.3% in the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after acquiring an additional 7,419,929 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new position in Pfizer in the first quarter worth about $311,238,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of a number of recent research reports. Truist Financial cut their target price on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 14th. Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Barclays dropped their price target on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 14th. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average target price of $36.88.

Pfizer Trading Down 0.5 %

Pfizer stock traded down $0.14 during midday trading on Thursday, reaching $26.18. The stock had a trading volume of 6,700,668 shares, compared to its average volume of 42,460,176. The firm’s fifty day simple moving average is $27.32 and its two-hundred day simple moving average is $29.00. Pfizer Inc. has a twelve month low of $25.61 and a twelve month high of $41.79. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The firm has a market cap of $148.25 billion, a price-to-earnings ratio of 72.78, a PEG ratio of 1.19 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter last year, the business posted $1.14 EPS. The company’s revenue was down 41.3% on a year-over-year basis. Equities analysts anticipate that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.